Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 62 clinical trials
featured
Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)

Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)

vascular disease
stroke
diabetes
atrial fibrillation
embolism
  • 314 views
  • 24 Nov, 2020
  • 1 location
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

(apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.

  • 0 views
  • 24 Jan, 2021
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension

and TIPSS (transjugular intrahepatic portosystemic shunt) or liver transplantation for severe cases. The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH

  • 0 views
  • 24 Jan, 2021
  • 1 location
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

atrial fibrillation. They also replaced oral and parenteral anticoagulants in the treatment and prevention of deep vein thrombosis. Among the 4 available NOACs today, only apixaban had received approval

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Apixaban for Extended Anticoagulation (APIDULCIS)

with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

deep vein thrombosis
venous thromboembolism
anticoagulation therapy
d-dimer
thrombosis
  • 6 views
  • 23 Jan, 2021
  • 1 location
Apixaban for the Acute Treatment of Venous Thromboembolism in Children

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

venous thromboembolism
anticoagulation therapy
heparin
apixaban
vitamin k
  • 0 views
  • 26 Jan, 2021
  • 164 locations
API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous

  • 8 views
  • 27 Jan, 2021
  • 70 locations
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by

anticoagulants
venous thromboembolism
rivaroxaban
apixaban
probe
  • 285 views
  • 27 Jan, 2021
  • 21 locations
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of ischemic stroke and systemic embolism in patients with device-detected sub-clinical atrial

vascular disease
stroke
ischemic stroke
diabetes
atrial fibrillation
  • 337 views
  • 26 Jan, 2021
  • 132 locations
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

aortic valve can be maintained safely and effectively on apixaban. Both the On-X aortic valve and apixaban have been approved for use by the US Food and Drug Administration (FDA) but they have not been

warfarin
aspirin
apixaban 5 mg
  • 79 views
  • 26 Jan, 2021
  • 69 locations